公开(公告)号：US20090028881A1

公开(公告)日：2009-01-29

申请号：US11893899

申请日：2007-08-17

Applicant: Michael Brandt ,  Stephan Fischer ,  Erhard Kopetzki ,  Suryanarayana Sankuratri ,  Ralf Schumacher

Inventor： Michael Brandt ,  Stephan Fischer ,  Erhard Kopetzki ,  Suryanarayana Sankuratri ,  Ralf Schumacher

IPC: C07K16/46 ,  A61K39/395 ,  C12P21/08 ,  A61P31/12 ,  A61P31/18

CPC classification number: C07K16/2866 ,  C07K14/005 ,  C07K2319/00 ,  C12N2740/16122

Abstract: The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.

Abstract translation: 本发明涉及包含一种或多种抗融合肽和抗CCR5抗体（mAb CCR5）的缀合物，其特征在于，一至八个抗融合肽各自与所述抗 - 抗体的重链和/或轻链的一个末端缀合， CCR5抗体和所述缀合物的药物用途。

公开(公告)号：US5602018A

公开(公告)日：1997-02-11

申请号：US374770

申请日：1995-02-07

Applicant: Erhard Kopetzki ,  Klaus Lehnert

Inventor： Erhard Kopetzki ,  Klaus Lehnert

IPC: G01N33/535 ,  C07K14/37 ,  C07K14/38 ,  C07K14/41 ,  C12N9/04 ,  C12N15/09 ,  C12N15/53 ,  C12Q1/26 ,  C12R1/685 ,  C12R1/865 ,  C12N1/14 ,  C12P21/06

CPC classification number: C12N9/0006

Abstract: Hypoglycosylated recombinant glucose oxidase with a molecular weight of ca. 68-80 kDa, a specific activity of ca. 200 U/mg unit of weight, a carbohydrate portion of ca. 12% which is obtainable by expression of a recombinant DNA containing the GOD gene in the N-glycosylation-defective yeast mutants DSM 7042, DSM 7338, DSM 7160 or DSM 7340 or allelic mutant strains, fermentation and isolation of the enzyme from the culture supernatant or the cells.

Abstract translation: PCT No.PCT / EP93 / 02054 Sec。 371日期：1995年2月7日 102（e）日期1995年2月7日PCT提交1993年8月2日PCT公布。 公开号WO94 / 03608 日期：1994年2月17日分子量约为的低聚糖重组葡萄糖氧化酶 68-80 kDa，比活性约为 200 U / mg单位重量，碳水化合物部分约 通过在N-糖基化缺陷型酵母突变体DSM 7042，DSM 7338，DSM 7160或DSM 7340或等位基因突变株中表达含有GOD基因的重组DNA获得的12％，可以从培养上清液中发酵和分离酶 或细胞。

公开(公告)号：US5434067A

公开(公告)日：1995-07-18

申请号：US100124

申请日：1993-07-30

Applicant: Uwe Michaelis ,  Rainer Rudolph ,  Michael Jarsch ,  Erhard Kopetzki ,  Helmut Burtscher ,  Gether Schumacher

Inventor： Uwe Michaelis ,  Rainer Rudolph ,  Michael Jarsch ,  Erhard Kopetzki ,  Helmut Burtscher ,  Gether Schumacher

IPC: C07K1/107 ,  C12N9/16 ,  C12N9/96 ,  C12N15/09 ,  C12N15/55 ,  C12N15/70 ,  C12R1/19 ,  C12N9/12 ,  C07K1/36 ,  C12N15/54

CPC classification number: C12N9/16

Abstract: In a process for the production of recombinant, biologically active, eukaryotic alkaline phosphatase a DNA sequence coding for a eukaryotic alkaline phosphatase is expressed in a prokaryotic host cell and the expression product is obtained in an active form by cell lysis, solubilization under denaturing conditions and subsequent renaturation. In this process the renaturation step is carried out in the presence of one or several stabilizing agents.

Abstract translation: 在生产重组，生物活性的真核碱性磷酸酶的过程中，在原核宿主细胞中表达编码真核碱性磷酸酶的DNA序列，通过细胞裂解，在变性条件下溶解获得活性形式的表达产物， 随后复性。 在该方法中，复性步骤在一种或几种稳定剂的存在下进行。

公开(公告)号：US5310876A

公开(公告)日：1994-05-10

申请号：US648796

申请日：1991-01-25

Applicant: Hubert Bayer ,  Erhard Kopetzki

Inventor： Hubert Bayer ,  Erhard Kopetzki

IPC: C07K19/00 ,  C07K14/00 ,  C07K14/155 ,  C07K14/16 ,  C12N1/21 ,  C12N15/09 ,  C12N15/49 ,  C12N15/62 ,  C12P21/02 ,  C12R1/19 ,  C12R1/92 ,  G01N33/535 ,  G01N33/543 ,  G01N33/569 ,  C07K3/00 ,  C07H15/12 ,  C12Q1/70

CPC classification number: C07K14/005 ,  C12N15/62 ,  G01N33/535 ,  G01N33/543 ,  G01N33/56988 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/735 ,  C12N2740/16122 ,  C12N2740/16222

Abstract: A fusion protein with at least one antigenic and/or immunogenic determinant from the env, gag and/or pol region of HIV1 and/or HIV2 which contains the tetrapeptide sequence NH.sub.2 -Met-Tyr-Tyr-Leu as the N-terminal component as well as a process for its production and use.

Abstract translation: 具有HIV1和/或HIV2的env，gag和/或pol区域的至少一种抗原和/或免疫原性决定簇的融合蛋白，其含有四肽序列NH2-Met-Tyr-Tyr-Leu作为N-末端成分，作为 以及其生产和使用的过程。

公开(公告)号：US10106600B2

公开(公告)日：2018-10-23

申请号：US13070582

申请日：2011-03-24

Applicant: Ulrich Brinkmann ,  Rebecca Croasdale ,  Harald Duerr ,  Christian Klein ,  Erhard Kopetzki ,  Wilma Lau ,  Joerg Thomas Regula ,  Juergen Michael Schanzer ,  Pablo Umana ,  Katharina Wartha

Inventor： Ulrich Brinkmann ,  Rebecca Croasdale ,  Harald Duerr ,  Christian Klein ,  Erhard Kopetzki ,  Wilma Lau ,  Joerg Thomas Regula ,  Juergen Michael Schanzer ,  Pablo Umana ,  Katharina Wartha

IPC: A61K39/00 ,  C07K16/22 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US09382323B2

公开(公告)日：2016-07-05

申请号：US12750748

申请日：2010-03-31

Applicant: Ulrich Brinkmann ,  Peter Bruenker ,  Rebecca Croasdale ,  Christian Klein ,  Erhard Kopetzki ,  Ekkehard Moessner ,  Joerg Thomas Regula ,  Juergen Michael Schanzer ,  Jan Olaf Stracke ,  Pablo Umana

Inventor： Ulrich Brinkmann ,  Peter Bruenker ,  Rebecca Croasdale ,  Christian Klein ,  Erhard Kopetzki ,  Ekkehard Moessner ,  Joerg Thomas Regula ,  Juergen Michael Schanzer ,  Jan Olaf Stracke ,  Pablo Umana

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2319/00

Abstract: The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Abstract translation: 本发明涉及包含全长抗体和单链Fab片段的多特异性，特别是双特异性抗体，其制备方法，含有该抗体的药物组合物及其用途。

公开(公告)号：US20130336972A1

公开(公告)日：2013-12-19

申请号：US13818465

申请日：2011-08-26

Applicant: Christian Klein ,  Erhard Kopetzki ,  Gerhard Niederfellner ,  Agnes Bernet ,  Celine Delloye-Bourgeois ,  Patrick Mehlen

Inventor： Christian Klein ,  Erhard Kopetzki ,  Gerhard Niederfellner ,  Agnes Bernet ,  Celine Delloye-Bourgeois ,  Patrick Mehlen

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K14/70503 ,  C07K2319/30

Abstract: The present invention relates to DCC-fusion proteins, nucleic acid molecules encoding the DCC-fusion proteins, as well as methods for their production and their use in treatment of cancer such as colorectal cancer, NSCLC and metastatic breast cancer. The present invention also relates to methods of treating cancer such as colorectal cancer, NSCLC and metastatic breast cancer by administering DCC-fusion proteins.

Abstract translation: 本发明涉及DCC融合蛋白，编码DCC-融合蛋白的核酸分子及其生产方法及其在治疗癌症如结肠直肠癌，NSCLC和转移性乳腺癌中的应用。 本发明还涉及通过施用DCC-融合蛋白来治疗癌症如结肠直肠癌，NSCLC和转移性乳腺癌的方法。

公开(公告)号：USRE43568E1

公开(公告)日：2012-08-07

申请号：US13187586

申请日：2011-07-21

Applicant: Yvo Graus ,  Jacques Himber ,  Miranda Jansen-Molenaar ,  Dorothee Kling ,  Erhard Kopetzki ,  Paul Parren ,  Frank Rebers ,  Beat Steiner ,  Anne Stern ,  Pamela Strein ,  Kay-Gunnar Stubenrauch ,  Jan Van de Winkel ,  Martine Van Vugt

Inventor： Yvo Graus ,  Jacques Himber ,  Miranda Jansen-Molenaar ,  Dorothee Kling ,  Erhard Kopetzki ,  Paul Parren ,  Frank Rebers ,  Beat Steiner ,  Anne Stern ,  Pamela Strein ,  Kay-Gunnar Stubenrauch ,  Jan Van de Winkel ,  Martine Van Vugt

IPC: A61K39/395 ,  C07K16/28

CPC classification number: C07K16/2854 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S435/81

Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).

Abstract translation: 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。

公开(公告)号：US07754867B2

公开(公告)日：2010-07-13

申请号：US12481623

申请日：2009-06-10

Applicant: Yvo Graus ,  Jacques Himber ,  Miranda Jansen-Molenaar ,  Dorothee Kling ,  Erhard Kopetzki ,  Paul Parren ,  Frank Rebers ,  Beat Steiner ,  Anne Stern ,  Pamela Strein ,  Kay-Gunnar Stubenrauch ,  Jan van de Winkel ,  Martine van Vugt

Inventor： Yvo Graus ,  Jacques Himber ,  Miranda Jansen-Molenaar ,  Dorothee Kling ,  Erhard Kopetzki ,  Paul Parren ,  Frank Rebers ,  Beat Steiner ,  Anne Stern ,  Pamela Strein ,  Kay-Gunnar Stubenrauch ,  Jan van de Winkel ,  Martine van Vugt

IPC: C12N15/13 ,  C12N15/12 ,  C12N15/63 ,  C12N5/10

CPC classification number: C07K16/2854 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S435/81

Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).

Abstract translation: 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。

公开(公告)号：US20090311725A1

公开(公告)日：2009-12-17

申请号：US12299918

申请日：2007-05-15

Applicant: Josef Endl ,  Erhard Kopetzki ,  Oliver Ploettner ,  Ursula Schwarz ,  Georg Tiefenthaler

Inventor： Josef Endl ,  Erhard Kopetzki ,  Oliver Ploettner ,  Ursula Schwarz ,  Georg Tiefenthaler

IPC: G01N33/53 ,  C07H21/00 ,  C12N5/06 ,  C12N5/08 ,  C12N15/63 ,  C12P21/00 ,  C12Q1/02

CPC classification number: C12N15/85 ,  C07K16/00 ,  C07K16/065 ,  C07K2319/03

Abstract: The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.

Abstract translation: 本发明描述了包含在5'至3'方向的核酸a）编码不具有​​帧内终止密码子的异源多肽的第一核酸，b）以5'剪接供体位点开始并以 3''剪接受体位点，其包含内部翻译终止密码子和多聚腺苷酸化信号，以及c）编码i）至少跨膜结构域片段的核酸，或ii）GPI锚的信号肽。